The country's health regulator has cleared the oral version of Novo Nordisk's semaglutide for weight management.
Recap by typeshit. Full story at Gulf Daily News (Bahrain).
Early trial results suggest the shot could one day help people hold onto weight loss after they come off GLP-1 drugs.
Bodybuilder Sam Sulek gives his take on peptides in a short clip from Chris Williamson's show. His views are his own, not medical guidance.
Superpower frames apitegromab's FDA approval as a big step and ties it to concern that GLP-1 users can lose a lot of muscle along with fat.
The telehealth company is also adding blood testing services alongside the lower costs for its compounded GLP-1 options.
A personal story about the control he felt on the drug and the cravings for it that followed once he stopped.
The CHMP opinion from 15 October now goes to the European Commission. In trials, people on the daily orforglipron tablet lost about 5% to 11% of body weight over 72 weeks.
Loading…